


Blueprint Medicines' FGFR4 inhibitor program was supported by joint  
CRELUX and WuXi AppTec drug discovery services

The discovery and preclinical development of a first selective inhibitor of FGFR4 for the treatment of Hepatocellular Carcinoma (HCC) was described in 2015 by [Hagel et al. in Cancer Discovery](#). Crelux supported Blueprint Medicines in this program with high purity protein for assays as well as with multiple X-ray complex structures. WuXi AppTec performed anti-tumor efficacy and PK/PD studies on select program compounds from Blueprint. Optimization within Blueprint led to the investigational clinical candidate BLU-554, which is currently in a Phase 1 clinical trial in HCC patients.

CRELUX and WuXi AppTec provide an open access platform for pharma and biotech companies, academic and public research organizations for the patient's benefits. WuXi AppTec has acquired Crelux in April 2016 which strengthens the biophysical screening and structure based drug discovery capabilities. With this acquisition also WuXi AppTec's first research site in Europe has been established to better serve the European Pharma and Biotech community.

As a WuXi AppTec company CRELUX continues to offer high-quality services. We can also provide our work now under just one standard WuXi AppTec master service agreement. Please [contact us](#) for further information on integrated or stand-alone drug discovery services.



FGFR4 complex structure solved at CRELUX. Picture kindly provided by Blueprint Medicines.

## CRELUX is now accredited for the French Research Tax Credit

CRELUX is approved by the French Ministry of Higher Education and Research for research tax credit (CIR) for a three-year period (**2016-2018**). This approval represents a recognition by the Ministry of expertise and skills of our company's to perform research and development. The French R&D tax credit initiative gives French companies, who are subject to corporate tax in France, the ability to claim tax relief on costs generated in R&D activities outsourced to CRELUX.

Please [contact us](#) if you need further information or a copy of the approval.

### Information importante **pour nos clients français**

La société Crelux a reçu l'accréditation pour le crédit d'impôt recherche (CIR). Le CIR constitue une aide fiscale qui permet aux entreprises de financer leurs activités de R&D et d'innovation, jusqu'à 30% de réduction sur les services de recherche fournis par CRELUX.

N'hésitez pas à nous contacter pour recevoir de plus amples informations ou une copie du document de l'accréditation.

CRELUX is your premium partner for collaborative drug discovery programs, protein supply, X-ray crystallography, biophysical analysis and fragment based screening services.

Please visit our website at [www.crelux.com](http://www.crelux.com) to learn more about the solutions we are providing to our growing number of clients.

---

## Meet us at

[BioEurope Spring](#), March 20-22, 2017, Barcelona, Spain

[Drug Discovery Chemistry](#), April 23-27, 2017, San Diego, CA, USA



CRELUX GmbH – a WuXi Apptec company - Am Klopferspitz 19a - 82152 Martinsried - GERMANY  
Dr. Michael Schaeffer - +49 (0)89 700 760 170 - [michael\\_schaeffer@wuxiapptec.com](mailto:michael_schaeffer@wuxiapptec.com)  
[www.crelux.com](http://www.crelux.com)

*Copyright © 2016 CRELUX GmbH, All rights reserved.*